Frencken Group (SGX: E28) is a Singapore-listed contract manufacturer whose semiconductor, medical and life sciences customers drive its numbers, and its 1H26 results show higher gross profit but slightly lower net profit.

For the six months to 30 June 2026, revenue was S$427.8m (down 0.8%), gross margin widened to 15.0% from 14.1%, yet net profit attributable to shareholders slipped 3.4% to S$19.3m. Management still guides for higher revenue and profit in FY2026, which means 2H26 has to do the heavy lifting.

This post runs Frencken through my VCBM checklist: Value, Catalyst, Business quality and Management.

Illustration of a robotic arm assembling a precision semiconductor equipment module on a factory floor

AI-generated illustration of precision contract manufacturing. Frencken builds modules and systems that other companies put their own names on.

What Is Frencken Group and How Does It Make Money?

Frencken is an investment holding company that provides design and manufacturing solutions out of Singapore, the Netherlands, China and Malaysia.

In plain terms, it is the factory behind the brand. Its customers hand over the design, or co-design it with Frencken, and Frencken builds the machine modules and systems.

Two divisions matter. Mechatronics is the big one, with FY2025 revenue of S$778.4m out of S$865.1m. Advanced Plastics Solutions (APS) is the smaller one at S$83.1m. Here are the numbers I would keep on one page.

Metric

FY2025

1H26 (to 30 Jun 2026)

Revenue

S$865.1m (up 8.9%)

S$427.8m (down 0.8%)

Gross margin

14.3%

15.0% (14.1% in 1H25)

Net profit to shareholders

S$39.1m (up 5.4%)

S$19.3m (down 3.4%)

Basic EPS

9.16 cents

4.50 cents (4.67 cents in 1H25)

Cash and borrowings

S$161.9m cash, S$22.3m borrowings

S$123.0m cash, S$54.2m borrowings

Dividend

2.75 cents final

No interim declared

The thing I notice first is the cash line. Net cash fell from roughly S$139.6m at the end of FY2025 to S$68.8m at 30 June 2026, by my arithmetic. The company has said a new Singapore facility is due by Q1 2027, which may be part of it, but that is my guess, not a statement from Frencken.

Value: What Is the Market Paying for Frencken?

This is the part of VCBM where the stock gets harder. A Simply Wall St article dated 14 August 2026 put the share price at S$2.63, down about 17% over the prior 90 days, with a trailing P/E of about 29x. It also said the price sat well above its own discounted cash flow estimate.

Using the FY2025 net asset value of 111.29 cents per share, S$2.63 works out to roughly 2.4 times book. For a business with a net margin of around 4.5%, that is not a cheap entry multiple.

The dividend does not do much for valuation either. The 2.75 cent final dividend is about 30% of FY2025 EPS of 9.16 cents (my arithmetic), and at S$2.63 it is a yield of about 1%. Moomoo data shows ex-dividend payouts of 4.13 cents in 2022, 3.64 cents in 2023, 2.28 cents in 2024, 2.61 cents in 2025 and 2.75 cents in 2026. This is a company that reinvests, not an income stock. If dividends are your focus, my guide to the best SGX dividend stocks is a better starting point.

Analysts are more positive than the multiples suggest. Moomoo shows eight analysts with an average target price of S$3.31, ranging from S$2.93 to S$3.76, as of 23 September 2026. Targets drift, so treat that as a mood reading, not an anchor.

200 Ways To Make Money With AI

Turns out, AI is good for more than writing emails and generating LinkedIn posts. This guide is packed with 200+ actionable ways to build income with AI.

Inside you'll discover:

  • 200 curated AI income ideas for beginners and pros alike

  • Easy-to-start opportunities you can launch this week

  • Real world applications for today’s top AI tools

  • AI powered business models built for today’s economy

  • Creative ways to turn trends into revenue

AI is changing how people work and how people earn, far beyond the simple “write me an email” prompt. Discover the possibilities and download the free guide to start cashing in today.

Catalyst: What Needs to Go Right in 2H26?

Management's own guidance sets the bar. In the 1H26 results announced on 13 August 2026, Frencken said it expects 2H26 revenue to exceed both 2H25 and 1H26, and FY2026 revenue and profit to be higher than FY2025, barring adverse changes in the external environment or currency volatility.

Let me turn that into numbers. FY2025 revenue was S$865.1m and 1H25 was S$431.4m, so 2H25 was about S$433.7m. For FY2026 profit to beat S$39.1m after a 1H26 of S$19.3m, 2H26 net profit needs to be above roughly S$19.8m, versus about S$19.2m in 2H25.

The company points to four things:

  • Semiconductor demand. Management cites projections of record global semiconductor equipment sales in 2026, and says its Asia and Europe operations are positioning for higher 2H26 volumes.

  • Analytical life sciences recovery. This segment fell 13.7% in 1H26, and management expects some recovery later in the year.

  • Automotive radar antennas. Production at APS is expected to ramp in 2H26.

  • The S$1 billion target. Management targets S$1 billion in annual revenue by 2028 if not earlier. From S$865.1m, that needs revenue growth of roughly 5% a year (my arithmetic).

Business Quality: Why Do Thin Margins Matter So Much?

Illustration of a balance scale weighing higher gross profit against rising operating costs

AI-generated illustration: gross profit rose in 1H26 but net profit did not.

Contract manufacturing is a volume game. Frencken keeps about 15 cents of every dollar of revenue as gross profit, and about 4.5 cents as net profit (FY2025 and 1H26 both land near 4.5%, my arithmetic). A small change in cost lines moves net profit a lot.

That is exactly what 1H26 showed. Gross profit rose 5.8% to S$64.4m, an increase of about S$3.5m by my arithmetic. Net profit still fell by about S$0.6m. So roughly S$4m of extra cost, tax, finance charges or currency effects absorbed the whole gross profit gain.

The segment mix explains some of the pressure on growth:

1H26 segment

Revenue

Change vs 1H25

Semiconductor

S$213.3m

Down 1.1%

Analytical life sciences

S$75.3m

Down 13.7%

Medical

S$70.5m

Up 10.1%

Industrial automation

S$18.4m

Up 9.8%

Mechatronics total

S$383.4m

Down 1.5%

APS division

S$42.0m

Up 3.6%

Semiconductor is about half of group revenue (S$213.3m of S$427.8m, my arithmetic), so the whole story rests on one cycle. Medical and industrial automation grew, but they are too small to offset a soft analytical life sciences line. The balance sheet is a quiet strength: Simply Wall St describes it as flawless, and even after the 1H26 drop the group holds net cash.

How Does Frencken Compare With Other SGX Tech Manufacturers?

Frencken sits in a small group of Singapore-listed names that build things for other companies. I have not pulled fresh numbers for the peers below, so this table compares business models only. Check each company's latest filing before comparing margins or valuation.

Company

What it does

Where it overlaps with Frencken

Frencken Group

Mechatronics and plastics solutions for semiconductor, medical, analytical and automotive customers

Not applicable

Venture Corporation

Technology products, design and manufacturing services across several industries

Contract manufacturing for technology and life sciences customers

UMS Integration

Equipment manufacturing and precision engineering, with a focus on semiconductor

Semiconductor equipment modules and precision machining

In plain terms, all three are the shop floor behind someone else's brand, so all three ride customer capex cycles.

What would set Frencken apart is the spread across medical, analytical and automotive. That spread did not save 1H26 profit, though, which is the honest crux of the comparison.

Get the Free Beyond Blue Chips E-book

Discover the V.C.B.M framework, four real SGX case studies and a practical 5-step plan for spotting SGX small and mid-cap stocks with strong long-term growth early.

Management: Does Frencken Deliver on Its Guidance?

This is the part I would watch most closely. When Frencken reported FY2025 results on 27 February 2026, it guided that 1H26 revenue would be largely unchanged and that net profit was expected to be higher, barring unforeseen circumstances.

1H26 item

Guided in Feb 2026

Actual (13 Aug 2026)

Revenue

Largely unchanged

S$427.8m, down 0.8%

Net profit

Expected to be higher

S$19.3m, down 3.4%

Revenue landed where management said. Profit did not. One half-year is a small sample, and the 15.0% gross margin shows the operations team is doing its job. Still, it is a reminder that guidance for a thin-margin business can miss on a few million dollars.

On ownership, Moomoo data dated 17 November 2026 lists Amova Asset Management at about 9.0%, Precico Holdings at about 8.9%, Sinn Hin Company at about 4.4%, Cayman Resources at about 3.1% and Meng Tak Corporation at about 3.0%, with individuals and insiders at about 8.5%.

Is Frencken Worth a Spot on the Watchlist?

Personally, I would file Frencken under good business, demanding price. The balance sheet is sound, the semiconductor cycle is a real tailwind per SEMI's projection, and the S$1 billion revenue goal gives a clear yardstick.

Against that, a trailing P/E of around 29x (as of mid August) leaves little room for a soft 2H26, and the 1H26 profit decline came with higher gross margin, which is the opposite of what you want to see.

What I would watch: whether the 3Q26 update shows revenue growth, whether analytical life sciences stabilises, and where net cash settles after the facility spend. If all three line up, the VCBM score improves. If not, the Value leg of the checklist stays weak.

What Are the Main Risks for Frencken?

  • Semiconductor concentration. About half of 1H26 revenue comes from this one cycle, so a pause in customer orders hits the whole group.

  • Thin margins. A net margin near 4.5% means small cost surprises swing profit, as 1H26 showed.

  • Currency. Management itself flags currency volatility as a swing factor for its guidance.

  • Weak analytical life sciences. Down 13.7% in 1H26, with recovery expected but not yet visible in the numbers.

  • Cash and spending. Net cash fell by roughly S$70m in 1H26 by my arithmetic.

  • Valuation. A rich multiple on thin margins leaves less margin of safety if guidance slips again.

What I would watch next is the 3Q26 update and the FY2026 results, expected around late February based on last year's timing.

Frequently Asked Questions

What does Frencken Group do?

Frencken designs and manufactures mechatronics modules and plastic components for other companies. Its customers span semiconductor, medical, analytical life sciences, industrial automation and automotive.

What is Frencken's SGX stock code?

Frencken Group trades on the SGX under the code E28. Its results announcements appear on SGXNet under that name.

Does Frencken pay dividends?

Yes, once a year. It paid a 2.75 cent final dividend for FY2025 with ex-dividend on 30 April 2026. No interim dividend was declared with the 1H26 results.

Can I use CPF or SRS to invest in Frencken?

Eligibility depends on your CPF or SRS operator and the current approved list, so check with your bank or broker before placing an order.

What is the minimum investment in Frencken?

It depends on the board lot size and the share price, and I have not verified the current lot size. Your broker's quote page shows it.

Is Frencken a semiconductor stock?

Partly. Semiconductor was S$213.3m of S$427.8m in 1H26, about half of revenue by my arithmetic, but the rest comes from medical, analytical life sciences, industrial automation and plastics.

Does Frencken have debt?

It carries some borrowings of S$54.2m, but it held S$123.0m in cash at 30 June 2026, leaving net cash of S$68.8m.

When does Frencken report next?

Last year the 3Q update came on 17 November and the full year results on 27 February.

What is the VCBM framework?

VCBM stands for Value, Catalyst, Business quality and Management. It is my checklist for small and mid-cap stocks. For another worked example, see my Pan-United VCBM analysis and my Mi Material post.

The Bottom Line

Frencken gives investors a well-run contract manufacturer with a net cash balance sheet, a widening gross margin and exposure to a semiconductor upcycle that industry bodies expect to be record-setting this year. That is a solid base.

The open question is conversion. Gross profit grew in 1H26 and net profit still fell, and management's February guidance on profit did not hold. Until profit follows revenue, the valuation has to be justified by 2H26 delivery.

Next, I would look at the 3Q26 update and the cash flow statement, and compare the numbers against management's own 2H26 guidance before forming a view.

Join our community for more insights:
https://investkaki.com/community

Cover of the e-book Beyond Blue Chips: The SGX Small and Mid-Cap Investing Playbook by James Yeo

Beyond Blue Chips: The SGX Small and Mid-Cap Investing Playbook

The V.C.B.M framework, four real SGX case studies and a practical 5-step plan to help you spot small and mid-cap stocks early. Free to download.